antiplatelets drug

Results Trial description recap V1

A EFFACER - Aspirin - Atopaxar - Cangrelor - Clopidogrel - Dipyridamol - Elinogrel - Prasugrel - Sulfinpyrazone - Ticagrelor - Ticlopidine - Triflusal - Vorapaxar

Acute coronary syndrome

STEMI patients 18 trials

patients not initialy planned for PCI 1 trials

ACS (excluding AMI) 22 trials

patients with scheduled percutaneous coronary intervention 3 trials

all type of patients 24 trials

Acute myocardial infarction

all type of patients 18 trials

CABG surgery

all type of patients 29 trials

Cardiovascular prevention

patients without established disease 11 trials

secondary prevention 7 trials

diabetic patients 14 trials

all type of patients 14 trials

secondary prevention in patients with intermittent claudication 34 trials

secondary prevention in patients with CAD 29 trials

primary prevention 9 trials

Diabetes type 2

patients without cardiovascular disease 14 trials

all type of patients 14 trials

Hypertension

all type of patients 1 trials

Percutaneous coronary intervention

PCI with DES placement 0 trials

all type of patients 29 trials

Peripheral vascular diseases

all type of patient 32 trials

Post myocardial infarction

all type of patient 15 trials

Post stroke

all type of patients 12 trials

Stent

antiplatelet therapy after stent placement (BMS or DES) 0 trials

Thrombosis prevention

general surgery 30 trials

all type of patients 46 trials

medical patients 4 trials

elective orthopedic surgery 16 trials

orthopedic surgery 46 trials